The genetic changes, however, meant that many of the edited trees grew much slower. Nevertheless, the team’s analysis suggested that the CRISPR-edited wood would likely boost fiber production ...

Free of CRISPR’s intellectual property mire ... as well as to boost the efficiency by which the cell’s protein-production machinery reads the genetic instructions encoded in RNA.

A Phase III trial evaluating nex-z in transthyretin amyloidosis with cardiomyopathy is underway, with plans for another ...

Cas9-mediated tools are the foundation of CRISPR technologies, setting the stage for new generation base editors and prime editors, and opening the door to genome editing therapeutics with greater ...

The data with the CRISPR/Cas9 drug CTX001 is still very early-stage, coming from just seven ... a gene known as BCL11A which down-regulates the production of the adult form of the oxygen-carrying ...

Crispr Therapeutics AG has revenue declines but holds strong financials. Promising Sickle Cell therapy & 2025 data readouts ...

CRISPR biotech Intellia Therapeutics has announced plans to reduce its workforce by 27% and halt early-stage R&D programmes as it concentrates resources on two late-stage drug candidates.

is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing ...